期刊
JOURNAL OF INFECTIOUS DISEASES
卷 217, 期 2, 页码 223-231出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix584
关键词
Ebola virus; Democratic Republic of the Congo; virus neutralization; serological response; filovirus
资金
- Bill and Melinda Gates Foundation [OPP1066684, OPP1151786, 20153705]
- Faucett Catalyst Fund, NIAID [R21AI107420]
- DFG [STE 2237/1-1]
- Fogarty International Center of the National Institutes of Health (NIH) [D43TW009343]
- University of California Global Health Institute (UCGHI)
- FOGARTY INTERNATIONAL CENTER [D43TW009343] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI107420, ZICAI009006, ZIDAI009006] Funding Source: NIH RePORTER
The first reported outbreak of Ebola virus disease occurred in 1976 in Yambuku, Democratic Republic of Congo. Antibody responses in survivors 11 years after infection have been documented. However, this report is the first characterization of anti-Ebola virus antibody persistence and neutralization capacity 40 years after infection. Using ELISAs we measured survivor's immunological response to Ebola virus Zaire (EBOV) glycoprotein and nucleoprotein, and assessed VP40 reactivity. Neutralization of EBOV was measured using a pseudovirus approach and plaque reduction neutralization test with live EBOV. Some survivors from the original EBOV outbreak still harbor antibodies against all 3 measures. Interestingly, a subset of these survivors' serum antibodies could still neutralize live virus 40 years postinitial infection. These data provide the longest documentation of both anti-Ebola serological response and neutralization capacity within any survivor cohort, extending the known duration of response from 11 years postinfection to at least 40 years after symptomatic infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据